Cytohesin inhibitors

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes novel pharmaceutical compositions containing specially designed primary and/or secondary amides that inhibit cytohesins, a family of proteins involved in cellular signaling pathways. These inhibitors show improved potency and selectivity over existing compounds and are particularly useful in treating diseases linked to malfunction of cytohesin-related signaling, such as autoimmune diseases, various cancers, metabolic dysfunctions like obesity, and for immunosuppression. The invention also suggests that these compounds may help extend lifespan via "chemically induced longevity."

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis, Crohn's disease, allergies, and mastocytosis.
• Therapy for various cancers, including lung, colon, pancreatic, rectal, prostate, lymphatic (leukemia), bladder, kidney, breast, and ovarian cancers.
• Prevention or therapy for metabolic disorders involving insulin and IGF signaling, such as obesity, age-related organ damage, and β-cell apoptosis.
• Immunosuppression in organ transplantation to reduce organ rejection.
• Anti-angiogenesis therapy for conditions involving abnormal blood vessel growth.
• Prevention or delay of aging and age-related cellular damage (chemically induced longevity).
• Treatment of developmental syndromes or conditions linked to cytohesin-dependent receptor tyrosine kinase hyperfunction (e.g., ErbB receptors).

BenefitsContent extracted from patent full text and abstract with AI.

• Stronger inhibition and selectivity against cytohesins compared to prior art, leading to better efficacy.
• Potential treatment across a broad spectrum of diseases involving immune, metabolic, and proliferative dysregulation.
• Possible use in both therapeutic and preventative (prophylactic) contexts, including pre-symptomatic intervention.
• Low toxicity allows for long-term or preventive administration, including oral dosing.
• Improved effectiveness at blocking cytohesin-mediated cell adhesion and interfering with insulin signaling, important in disease pathology.
• Potential for extending mammal (including human) lifespan without genetic or surgical intervention.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a pharmaceutical preparation comprising as an active ingredient a primary amide according to the general formula (1) and/or a secondary amide according to the general formula (2) and their use as a medicament.